Media

Press releases

Placeholder image of a document icon

Mundipharma wins 1st ever PLG deal of the year award for acquisition of Cinfa Biotech

Win recognises the significance of the deal in enabling Mundipharma to further enhance Mundipharma’s biosimilar platform offering Cambridge. 26th February 2019  – The Mundipharma network of independent associated companies is delighted to anno...continue reading

Placeholder image of a document icon

Mundipharma launches Pelmeg®▼ (pegfilgrastim) biosimilar in Europe

Germany, the Netherlands and Ireland are the first markets to launch Pelmeg®. Pelmeg, a pegfilgrastim biosimilar, is indicated for the reduction of the duration of neutropenia and incidence of febrile neutropenia in adults treated with chemotherapy....continue reading

Placeholder image of a document icon

European Commission approves Pelmeg▼® (pegfilgrastim) as a biosimilar treatment to reduce the duration of neutropenia and incidence of febrile neutropenia in adults treated with chemotherapy

Pelmeg is a pegfilgrastim biosimilar that is delivered subcutaneously to reduce the duration of neutropenia and the incidence of febrile neutropenia in adult patients treated with cytotoxic chemotherapy for malignancy (with the exception of chronic ...continue reading